About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72808 record(s)
Req # A-2023-001486
Correspondence relating to any Abbreviated New Drug Submission (ANDS) accepted into review as of February 22, 2024 where the medicinal ingredient is degarelix acetate and the correspondence mentions “bio-waiver”.Organization: Health Canada
May 2024
Req # A-2023-001487
Records containing information regarding the evidence of clinical effectiveness of the Degarelix Abbreviated New Drug Submission (ANDS) for the purpose and under the conditions of use recommended, as described in the Food and Drug Regulations.Organization: Health Canada
May 2024
Req # A-2023-001506
From February 28, 2023-February 29, 2024, final versions of all briefing notes / memos/ anticipated media Questions & Answers regarding Kenneth Law and/or Sodium nitrite and it’s use as a suicide substance that were sent to/received by: Minister…Organization: Health Canada
May 2024
Req # A-2023-001523
In respect of the First Liraglutide Abbreviated New Drug Submission (ANDS), please provide the name of the company who submitted this ANDS.Organization: Health Canada
May 2024
Req # A-2023-001527
As of December 15, 2023, there are now two liraglutide submissions which appear on the Generic Submissions Under Review (GSUR) List. Provide the name of the company who submitted the Abbreviated New Drug Submission (ANDS); and the year and month in…Organization: Health Canada
May 2024
Req # A-2023-001536
As part of its application to Health Canada for authorization to sell the COVID-19 lateral flow device with the Interim Order (IO) authorization Identification 327866, the manufacturer sent the federal government about 200 sample tests. Provide the…Organization: Health Canada
May 2024
Req # A-2023-001537
As part of its application to Health Canada for authorization to sell the three COVID-19 lateral flow devices with the Interim Order (IO) authorization Identifications 313054, 328889, and 333956, the manufacturer sent the federal government about…Organization: Health Canada
May 2024
Req # A-2023-001572
Any security related training completed by Nadine Huggins, the Senior Assistant Deputy Minister (ADM) and Chief Security officer at Health Canada.Organization: Health Canada
May 2024
Req # A-2023-001628
All communications originating from atrazine registrants, or their agents or representatives including the triazine network to the Pest Management Regulatory Agency (PMRA) regarding the aquatic reference values for atrazine and all PMRA internal…Organization: Health Canada
May 2024
Req # A-2024-000044
Documents and records containing information regarding the mock-ups of every label to be used in connection with the Fourth Desmopressin Abbreviated New Drug Submission (ANDS) and mock-ups of the drug product’s packages, as described in the Food and…Organization: Health Canada
May 2024